CN101795694A - Injection, injection solution and injection kit preparation - Google Patents
Injection, injection solution and injection kit preparation Download PDFInfo
- Publication number
- CN101795694A CN101795694A CN200880105380A CN200880105380A CN101795694A CN 101795694 A CN101795694 A CN 101795694A CN 200880105380 A CN200880105380 A CN 200880105380A CN 200880105380 A CN200880105380 A CN 200880105380A CN 101795694 A CN101795694 A CN 101795694A
- Authority
- CN
- China
- Prior art keywords
- injection
- antibiotic
- malignant tumor
- nicotiamide
- anthracene nucleus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
An injection which comprises an anthracycline antibiotic against malignant tumor and at least one acid amide selected from the group consisting of nicotinic acid amide, isonicotinic acid amide and gentisic acid ethanolamide.
Description
Technical field
The instant capacity injection that the present invention relates to improve the antibiotic dissolubility of anthracene nucleus class anti-malignant tumor and get, and the injection and the injection kit preparation that use this injection.
Background technology
Anthracene nucleus class anti-malignant tumor antibiotic is strong antitumor antibiotic, is widely used in treating malignant lymphoma, leukemia, breast carcinoma etc.Usually make injection (injection) mostly to patient's medication.
The antibiotic injection of anthracene nucleus class anti-malignant tumor can dissolve with distilled water for injection, but because distilled water for injection may be stronger than normal saline to the zest of bladder, thereby in order to relax when injection pain of producing of patient, these injection most cases are to use physiological saline solution, with blood and/or the isoosmotic state of body fluid under use.But the agent of the known anthracene nucleus class of people anti-malignant tumor injection of antibiotic overlaps each other owing to the pi-electron cloud takes place charged materials such as normal saline, usually becomes piece, and (referring to document 1: injection drug cooperates and changes Q﹠amp to need the time during dissolving; A, じ ほ う,, 61～62 pages in 2006).
Therefore, people have attempted improving the deliquescent method of anthracene nucleus class anti-malignant tumor antibiotic to normal saline.For example, the method for adding organic solvents such as ethanol when making preparation (referring to document 2: the spy opens flat 7-76515 communique) is disclosed.But, because of the problem of operation still is in unenforced situation.In addition, also disclose in the anthracene nucleus glucosides use methyl parahydroxybenzoate etc. (parabens) as and with solubilizing agent (referring to document 3: the spy opens clear 61-246129 communique).
When medicine is made injection, need be dissolved in the required solvent.But, because the physicochemical properties of medicine are different because of the difference of various medicines, thereby because solvent types and can not consoluet situation more.Therefore, in order to make the dissolving rapidly in required solvent of various medicines, attempted using various cosolvents to dissolve.
But, can dissolved substance even people are known, also owing to add that cosolvent can produce the stability of drug variation on the contrary, injection is painted or so-called incompatibility such as decomposition.Therefore, find the good specific cosolvent of the compatibility of various medicines and be not easy.
Therefore, in order to realize deliquescent improvement in various injections, people have studied the application of cosolvent.For example, in having the antibiotic Amythiamicin of antibiotic property, use aromatic carboxylic acid as cosolvent (referring to document 4: the spy opens flat 9-124503 communique).In addition, in the anti-inflammatory analgesic loxoprofen sodium, use alkali such as sodium hydroxide as cosolvent (referring to document 5: special table 2004-515526 communique).
Summary of the invention
About the antibiotic injection of anthracene nucleus class anti-malignant tumor, it dissolves the required time fully in normal saline very long, becomes burden bigger in the operation for medical practitioner's use.In addition, owing to accidentally just can not dissolve in effective time when adding normal saline, thereby expensive injection goes out of use, and not only causes bigger economic loss, and hinders government to promote the work of medical care expenses inhibition.Therefore, even wishing that exploitation is a kind of also can be easily in the presence of normal saline and promptly dissolve anthracene nucleus class anti-malignant tumor antibiotic and this antibiotic do not produced the injection of baneful influence such as incompatibility.
Present inventors further investigate the dissolubility of normal saline for the agent of improvement anthracene nucleus class anti-malignant tumor injection of antibiotic, found that, by adding specific cyclic amide such as nicotiamide, Pyrazinamide or gentisic acid ethanolamine as cosolvent, thereby can not produce baneful influences such as incompatibility to anthracene nucleus class anti-malignant tumor antibiotic, even and in the presence of normal saline, also can dissolve this antibiotic rapidly, thereby finished the present invention.
The present invention relates to following＜1 〉～＜6.
＜1〉a kind of injection contains: anthracene nucleus class anti-malignant tumor antibiotic; And be selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
＜2〉as＜1〉described injection, described anthracene nucleus class anti-malignant tumor antibiotic is to be selected from aclarubicin hydrochloride (Aclarubicin hydrochloride), Amrubicin Hydrochloride (Amrubicinhydrochloride), hydrochloric acid darubicin (Idarubicin hydrochloride), epirubicin hydrochloride (Epirubicin hydrochloride), daunorubicin hydrochloride (Daunorubicin hydrochloride), doxorubicin hydrochloride (Doxorubicin hydrochloride), at least a material in NSC 654509 (pirarubicinhydrochloride) and the mitoxantrone hydrochloride (mitoxantrone hydrochloride).
＜3〉as＜1〉described injection, the content of described amide is 0.75～12.5mg with respect to every 1mg (tiring) anthracene nucleus class anti-malignant tumor antibiotic.
＜4〉a kind of injection contains: anthracene nucleus class anti-malignant tumor antibiotic; Be selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine; And lysate.
＜5〉a kind of injection kit preparation comprises: through the antibiotic injection of cryodesiccated anthracene nucleus class anti-malignant tumor; And contain the lysate that is selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
＜6〉a kind of injection kit preparation comprises: through the antibiotic injection of cryodesiccated anthracene nucleus class anti-malignant tumor; And be filled with the container that is selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
According to the present invention, by adding specific cyclic amide such as nicotiamide, Pyrazinamide or gentisic acid ethanolamine as cosolvent, even thereby in the presence of normal saline, also can dissolve anthracene nucleus class anti-malignant tumor antibiotic rapidly, therefore can realize improving treatment time efficient and/or medical practitioner's operation.And then, according to the present invention, can therefore can fully keep the stability of injection and the stability of dissolving back injection not improving dissolubility under the state to baneful influences such as anthracene nucleus class anti-malignant tumor antibiotic generation incompatibilitys.
The specific embodiment
At first, describe for injection of the present invention and injection.
Injection of the present invention contains: anthracene nucleus class anti-malignant tumor antibiotic; And be selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
In addition, injection of the present invention contains: anthracene nucleus class anti-malignant tumor antibiotic; Be selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine; And lysate.
In injection of the present invention and the injection, be combined with at least a cyclic amide that is selected from nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.By adding this specific cyclic amide, can not produce baneful influences such as incompatibility, even and in the presence of normal saline, also can dissolve this antibiotic rapidly to anthracene nucleus class anti-malignant tumor antibiotic as cosolvent.
Amount as the above-mentioned specific amide in injection of the present invention and the injection, not restriction especially, from coming to alleviate the angle consideration of the operational burden of medical practitioner by improving dissolubility from the body sense, be more than the 0.75mg preferably, more preferably more than the 1.00mg with respect to every 1mg (tiring) anthracene nucleus class anti-malignant tumor antibiotic.On the other hand, about the amount of above-mentioned specific amide capping especially, if but consider to use precedent, be below the 12.5mg preferably then with respect to every 1mg (tiring) anthracene nucleus class anti-malignant tumor antibiotic.
As the anthracene nucleus class anti-malignant tumor antibiotic that uses among the present invention, can enumerate aclarubicin hydrochloride, Amrubicin Hydrochloride, hydrochloric acid darubicin, epirubicin hydrochloride, daunorubicin hydrochloride, doxorubicin hydrochloride, NSC 654509, mitoxantrone hydrochloride etc.Wherein, preferred daunorubicin hydrochloride, doxorubicin hydrochloride, NSC 654509.
The antibiotic salt of so-called anthracene nucleus class anti-malignant tumor of the present invention, so long as the salt that allows on the pharmacopedics gets final product, not restriction especially, preferred salt hydrochlorate, sulfate, nitrate, acetate, phosphate, benzoate, maleate, fumarate, succinate, hydrobromate, hydriodate, tartrate, oxalates, citrate, aspartate, mesylate, methane-disulfonic acid salt, esilate, propane sulfonic acid salt, glyoxylate, benzene sulfonate etc.
To the not restriction especially of manufacture method of injection of the present invention, can adopt conventional method.As general method, for example, anthracene nucleus class anti-malignant tumor antibiotic, excipient and above-mentioned specific amide are dissolved in the distilled water for injection, regulate pH value and obtain lysate with the pH regulator agent.Then, this lysate is carried out aseptic filtration with filter membrane, the lysate branch of this ormal weight is installed in the vial, and carry out lyophilization, thereby can make injection of the present invention.
As excipient, can add lactose, mannitol, Sorbitol, glucosan, glucose etc.In addition, as the pH regulator agent, can enumerate hydrochloric acid, sodium hydroxide etc.
The container of the above-mentioned lysate of packing is not limited to vial, also can use ampoule and/or prefilled syringe etc.
In the scope of not damaging purpose of the present invention, can further use the additive that uses in the common injection that pharmaceutically allows in the injection of the present invention.As these additives, can enumerate antiseptic, analgesics, antioxidant etc.As antiseptic, can enumerate methyl parahydroxybenzoate, propyl p-hydroxybenzoate, thiomersalate, methaform etc.As analgesics, can enumerate benzyl alcohol, Mepivacaine Hydrochloride, lidocaine hydrochloride etc.As antioxidant, can enumerate ascorbic acid, sodium sulfite, sodium sulfite etc.
To using injection of the present invention to obtain the also not restriction especially of method of injection of the present invention, can adopt conventional method.As conventional method, for example, the injection of the invention described above can be dissolved with lysate facing the time spent, thereby obtain injection of the present invention.To the not restriction especially of described lysate, preferably use distilled water for injection, saline, Glucose Liquid etc.In addition, the concentration of the injection that the amount of lysate can be when using is suitably regulated and is used.
Below, describe for injection kit preparation of the present invention.
First injection kit preparation of the present invention comprises: through the antibiotic injection of cryodesiccated anthracene nucleus class anti-malignant tumor; And contain the lysate that is selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
In addition, second injection kit preparation of the present invention comprises: through the antibiotic injection of cryodesiccated anthracene nucleus class anti-malignant tumor; And be filled with the container that is selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
Employed in first and second injection kit preparations of the present invention through the agent of cryodesiccated anthracene nucleus class anti-malignant tumor injection of antibiotic, except not containing above-mentioned specific amide, can be the injection same with the injection of the invention described above, for example, except not adding above-mentioned specific amide, can be by making with the same method of the manufacture method of the injection of the invention described above.
On the other hand, as the employed lysate that contains above-mentioned specific amide in first injection kit preparation of the present invention, the preferably aqueous solution that obtains with the above-mentioned specific amide of dissolvings such as distilled water for injection and/or normal saline.This lysate can use in the mode that is filled in vial, ampoule, the prefilled syringe etc.
In addition, as the employed container that is filled with above-mentioned specific amide in second injection kit preparation of the present invention, preferably pulverous above-mentioned specific amide is filled in the employed containers of injection such as vial, ampoule, prefilled syringe to be made.In this case, can dissolve with lysates such as distilled water for injection and/or normal saline in use and use.In addition, in this case, in the scope of not damaging purpose of the present invention, can also add employed additive in the common injection that pharmaceutically allows.
Amount as employed above-mentioned specific amide in first and second injection kit preparations of the present invention, not restriction especially, from coming to alleviate the viewpoint consideration of the operational burden of medical practitioner by improving dissolubility from the body sense, be more than the 0.4mg preferably, more preferably more than the 1.0mg with respect to every 1mg (tiring) anthracene nucleus class anti-malignant tumor antibiotic.On the other hand, for the amount of above-mentioned specific amide capping especially,, be below the 12.5mg preferably then with respect to every 1mg (tiring) anthracene nucleus class anti-malignant tumor antibiotic if consider to use precedent.
Embodiment
Below, be described more specifically the present invention based on embodiment and comparative example, but the present invention is not limited to following embodiment.
In addition, use following chemical compound as each chemical compound
NSC 654509: with respect to 10mg (tiring) pirarubicin (Mingzhi makes Fruit (strain) system), the hydrochloric acid 0.0014mL that adds concentration 35% modulates.
Pirarubicin for injection (therarubicin): common name " pirarubicin (Pirarubicin) ", Mingzhi make Fruit (strain) system
Daunorubicin: Mingzhi makes Fruit (strain) system
Darubicin: Off ア イ ザ one society's system
Doxorubicin: consonance fermentation industry society system
Epirubicin: Off ア イ ザ one society's system
Aclarubicin: メ Le シ ヤ Application society system
Nicotiamide: organic synthesis pharmaceutical industries society system
Pyrazinamide: and the pure pharmaceutical worker's industry of light society system
Gentisic acid ethanolamine: hydrops メ デ イ カ Le (old first chemical drugs) society's system
Nicotinic acid: and the pure pharmaceutical worker's industry of light society system
N, N '-dimethyl acetylamide: and the pure pharmaceutical worker's industry of light society system
Methyl parahydroxybenzoate: Na カ ラ イ テ ス Network society system
Urea: pure chemical society system
Polysorbate 20: daylight ケ ミ カ Le ズ society system
Macrogol 4000: day oily society system
Polyoxyethylene (160) polyoxypropylene (30) glycol: BASF society system
Citric acid: pure chemical society system
Sodium ethylene diamine tetracetate: colleague's chemistry institute society system.
(Production Example 1) is combined with the manufacturing of the injection of nicotiamide 20mg
NSC 654509 1.6g (tiring), nicotiamide 1.6g and lactose 14.4g are dissolved in the distilled water for injection, are adjusted to pH6, obtain the lysate of total amount 240mL with the 0.01mol/L sodium hydrate aqueous solution.This lysate is carried out aseptic filtration, and the capacity of being filled into is in the vial of 10mL, carries out lyophilization then.After the drying, rubber stopper obtains 80 of injections of the present invention beyond the Great Wall.
(Production Example 2) is combined with the manufacturing of the injection of nicotiamide 80mg
NSC 654509 1.6g (tiring), nicotiamide 6.4g and lactose 14.4g are dissolved in the distilled water for injection, are adjusted to pH6, obtain the lysate of total amount 240mL with the 0.01mol/L sodium hydrate aqueous solution.This lysate is carried out aseptic filtration, and the capacity of being filled into is in the vial of 10mL, carries out lyophilization then.After the drying, rubber stopper obtains 80 of injections of the present invention beyond the Great Wall.
(relatively Production Example 1) mismatches the manufacturing of the injection of above-mentioned specific amide
NSC 654509 1.6g (tiring) and lactose 14.4g are dissolved in the distilled water for injection, are adjusted to pH6, obtain the lysate of total amount 240mL with the 0.01mol/L sodium hydrate aqueous solution.This lysate is carried out aseptic filtration, and the capacity of being filled into is in the vial of 10mL, carries out lyophilization then.After the drying, rubber stopper obtains 80 of injections beyond the Great Wall.
＜test example 1: embodiment 1～3 and comparative example 1～9〉be combined with the dissolubility test of the injection of various cosolvents
Various cosolvents shown in the table 1 are dissolved among the distilled water for injection 3mL by use level shown in this table, again this liquid are added among the pirarubicin for injection 20mg, it is dissolved fully, make each solution and Production Example 1 lyophilization similarly that obtain, make injection.Then, in each injection that obtains, add normal saline 10mL and vibrate, confirm antibiotic dissolubility.
Its result is as shown in table 1, in the injection that has cooperated nicotiamide, Pyrazinamide, gentisic acid ethanolamine, antibiotic dissolves at short notice to normal saline, but in the injection that has cooperated other cosolvents, antibiotic does not dissolve at short notice to normal saline.In addition, the cosolvent use level is to consider to use the maximum of precedent to cooperate.
[table 1]
| The embodiment comparative example | Cosolvent | Use level | Dissolubility |
| Embodiment 1 | Nicotiamide | ??250mg | 30 seconds with interior dissolving |
| Embodiment 2 | Pyrazinamide | ??250mg | 60 seconds with interior dissolving |
| Embodiment 3 | The gentisic acid ethanolamine | ??100mg | 30 seconds with interior dissolving |
| Comparative example 1 | Nicotinic acid | ??60mg | Do not dissolve with interior in 10 minutes |
| Comparative example 2 | N, N '-dimethyl acetylamide | ??300mg | Do not dissolve with interior in 10 minutes |
| Comparative example 3 | Methyl parahydroxybenzoate | ??2mg | Do not dissolve with interior in 10 minutes |
| Comparative example 4 | Urea | ??50mg | Do not dissolve with interior in 10 minutes |
| The embodiment comparative example | Cosolvent | Use level | Dissolubility |
| Comparative example 5 | Polysorbate 20 | ??80mg | Do not dissolve with interior in 10 minutes |
| Comparative example 6 | Macrogol 4000 | ??120mg | Do not dissolve with interior in 10 minutes |
| Comparative example 7 | Polyoxyethylene (160) polyoxypropylene (30) | ??10mg | Do not dissolve with interior in 10 minutes |
| Comparative example 8 | Citric acid | ??0.4mg | Do not dissolve with interior in 10 minutes |
| Comparative example 9 | Sodium ethylene diamine tetracetate | ??1.7mg | Do not dissolve with interior in 10 minutes |
＜test example 2: embodiment 4～8 and comparative example 10～14〉the antibiotic dissolubility test of various anthracene nucleus class anti-malignant tumors
Various anthracene nucleus class anti-malignant tumor antibiotic shown in the table 2 by use level shown in this table, are dissolved among the distilled water for injection 2mL that is combined with nicotiamide 160mg, make each solution and Production Example 1 lyophilization similarly that obtain, make injection (embodiment 4～8).In addition, except mismatching nicotiamide, similarly make injection, make reference substance (comparative example 10～14) with embodiment 4～8.Then, when in each injection that obtains, adding 10% saline and vibrate, in the time of 30 seconds, confirm antibiotic dissolubility.
Its result is as shown in table 2, is not cooperating in anthracene nucleus class anti-malignant tumor antibiotic in the injection of nicotiamide, and antibiotic does not dissolve fully to saline, but in the injection that has cooperated nicotiamide, antibiotic all dissolves at short notice to saline.In addition, the antibiotic name is represented with common name.
[table 2]
＜test example 3: embodiment 9～11 and comparative example 15〉dissolubility test in the different injection of nicotiamide use level
As shown in table 3, respectively according to the method same, make the different injection (embodiment 9～11 and comparative example 15) of addition of nicotiamide with Production Example 1.Then, in each injection that obtains, add normal saline 10mL, and the vibration vial, through the time ground confirm antibiotic dissolved state, measure to the consoluet time of antibiotic.
Its result is as shown in table 3, and in not adding the reference substance injection of nicotiamide, dissolving fully to antibiotic need be more than 10 minute, and Halfway Stopping is measured.On the other hand, in the nicotiamide addition was injection more than the 20mg, antibiotic dissolved rapidly.In addition, can confirm that the many more dissolution times of addition of nicotiamide are short more, if addition is that then dissolubility improves rapidly more than the 20mg, dissolving is carried out rapidly.
[table 3]
| Comparative example 15 (reference substance) | Embodiment 9 (prescription 1) | Embodiment 10 (prescription 2) | Embodiment 11 (prescription 3) | |
| NSC 654509 | 20mg (tiring) | 20mg (tiring) | 20mg (tiring) | 20mg (tiring) |
| Nicotiamide | ??- | ??15mg | ??20mg | ??80mg |
| Lactose | ??180mg | ??180mg | ??180mg | ??180mg |
| Sodium hydroxide | In right amount | In right amount | In right amount | In right amount |
| Injection is steamed and is stayed water | Making total amount is the amount of 3mL | Making total amount is the amount of 3mL | Making total amount is the amount of 3mL | Making total amount is the amount of 3mL |
| Dissolution time | More than 10 minutes | 8 minutes 10 seconds | 10 seconds | 5 seconds |
＜test example 4: embodiment 12 and comparative example 16〉stress test of injection
Use the injection (containing nicotiamide 20mg) of Production Example 1 manufacturing, under 40 ℃ temperature conditions, place, after through the holding time shown in the table 4, measure the survival rate of pirarubicin.In addition, the injection that uses comparison Production Example 1 manufacturing do not cooperate nicotiamide is product in contrast, measure the survival rate of pirarubicin equally.
Its result is as shown in table 4, and the injection of Production Example 1 manufacturing shows to have equal stability (survival rate of pirarubicin) with the reference substance that does not contain nicotiamide.That is,, can not produce baneful influences such as incompatibility to the main constituent pirarubicin even can confirm to cooperate nicotiamide yet.
[table 4]
＜test example 5: embodiment 13～17 and comparative example 17〉dissolubility test of lysate of nicotiamide
In pirarubicin for injection 20mg (tiring), add being dissolved in the lysate 10mL of the nicotiamide in the normal saline and vibrating, confirmed antibiotic dissolubility every 30 seconds by the use level shown in the table 5.
Its result is as shown in table 5, can confirm by adding nicotiamide pirarubicin is dissolved in the normal saline.Thereby can confirm can make anthracene nucleus class anti-malignant tumor antibiotic pirarubicin solvent by adding nicotiamide as its lysate, even also can make the pirarubicin dissolving with the normal saline coexistence simultaneously.
[table 5]
| The embodiment comparative example | Nicotiamide addition (mg) | Dissolution time |
| Comparative example 17 | Do not have and add | More than 10 minutes |
| Embodiment 13 | ??8 | 120 seconds |
| Embodiment 14 | ??15 | 120 seconds |
| Embodiment 15 | ??20 | 60 seconds |
| Embodiment 16 | ??80 | In 30 seconds |
| Embodiment 17 | ??250 | In 30 seconds |
The industry utilizability
According to the present invention, can not produce the baneful influences such as incompatibility to anthracycline anti-malignant tumor antibiotic, even and also can dissolve rapidly this antibiotic in the presence of physiological saline, so the present invention is very useful as the technology that contains the antibiotic injection of anthracycline anti-malignant tumor and parenteral solution is provided.
Claims (6)
1. an injection contains: anthracene nucleus class anti-malignant tumor antibiotic; And be selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
2. injection as claimed in claim 1, described anthracene nucleus class anti-malignant tumor antibiotic is at least a material that is selected from aclarubicin hydrochloride, Amrubicin Hydrochloride, hydrochloric acid darubicin, epirubicin hydrochloride, daunorubicin hydrochloride, doxorubicin hydrochloride, NSC 654509 and the mitoxantrone hydrochloride.
3. injection as claimed in claim 1, the content of described amide is 0.75～12.5mg with respect to the anthracene nucleus class anti-malignant tumor antibiotic of every 1mg (tiring).
4. an injection contains: anthracene nucleus class anti-malignant tumor antibiotic; Be selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine; And lysate.
5. an injection kit preparation comprises: through the antibiotic injection of cryodesiccated anthracene nucleus class anti-malignant tumor; And contain the lysate that is selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
6. an injection kit preparation comprises: through the antibiotic injection of cryodesiccated anthracene nucleus class anti-malignant tumor; And be filled with the container that is selected from least a amide in nicotiamide, Pyrazinamide and the gentisic acid ethanolamine.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007228516 | 2007-09-04 | ||
| JP228516/2007 | 2007-09-04 | ||
| PCT/JP2008/065865 WO2009031577A1 (en) | 2007-09-04 | 2008-09-03 | Injection, injection solution and injection kit preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101795694A true CN101795694A (en) | 2010-08-04 |
| CN101795694B CN101795694B (en) | 2012-10-10 |
Family
ID=40428891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801053808A Active CN101795694B (en) | 2007-09-04 | 2008-09-03 | Injection, injection solution and injection kit preparation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8227430B2 (en) |
| EP (1) | EP2184066B1 (en) |
| JP (1) | JP4456177B2 (en) |
| KR (1) | KR101511398B1 (en) |
| CN (1) | CN101795694B (en) |
| BR (1) | BRPI0816364B8 (en) |
| ES (1) | ES2439497T3 (en) |
| HK (1) | HK1142820A1 (en) |
| MX (1) | MX2010001263A (en) |
| WO (1) | WO2009031577A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614118A (en) * | 2012-03-15 | 2012-08-01 | 北京协和药厂 | Preparation method for epirubicin hydrochloride preparation for injection and preparation |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013154045A1 (en) * | 2012-04-09 | 2013-10-17 | 日本マイクロバイオファーマ株式会社 | Composition for injectable solution |
| JP7001454B2 (en) | 2017-12-18 | 2022-01-19 | 日本化薬株式会社 | Pharmaceutical product containing fosaprepitant |
| LU101511B1 (en) * | 2019-12-02 | 2021-06-04 | Herrera Arturo Solis | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a parenteral administration and a process for the preparation of an injectable substance |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB485569A (en) * | 1936-11-17 | 1938-05-17 | Ig Farbenindustrie Ag | Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines |
| JPS58105917A (en) * | 1981-12-21 | 1983-06-24 | Toa Eiyou Kagaku Kogyo Kk | Solution of isosorbide nitrate |
| GB8426672D0 (en) * | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| EP0438183B1 (en) * | 1986-12-05 | 1995-11-08 | PHARMACIA S.p.A. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US4875311A (en) * | 1988-04-20 | 1989-10-24 | Sun Room Designs, Inc. | Beam construction |
| JP2919112B2 (en) | 1991-05-13 | 1999-07-12 | 武田薬品工業株式会社 | Cephalosporin injection and production method thereof |
| JP2915252B2 (en) * | 1993-06-30 | 1999-07-05 | 明治製菓株式会社 | Method for producing a formulation with improved solubility |
| TW280770B (en) * | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
| JPH09124503A (en) | 1995-10-27 | 1997-05-13 | L T T Kenkyusho:Kk | Antimicrobial composition for injection of amythiamicins |
| JP2000212088A (en) * | 1999-01-27 | 2000-08-02 | Kobayashi Kako Kk | Aqueous solution of slightly soluble antiviral agent |
| KR100405161B1 (en) | 2000-12-14 | 2003-11-12 | 신풍제약주식회사 | Pharmaceutical composition for intramuscular injection containing loxoprofen |
| US6881726B2 (en) * | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
| JP2003261449A (en) * | 2002-03-05 | 2003-09-16 | Nisshin Oillio Ltd | Famotidine-containing aqueous injection preparation and method for producing the same |
| JP2004010479A (en) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | New solid pharmaceutical preparation comprising block copolymer and anthracycline anticancer agent, and method for producing the same |
| JP2004051526A (en) | 2002-07-18 | 2004-02-19 | Nippon Shokubai Co Ltd | Method for producing polyhydric phenol |
| EP1695973A1 (en) * | 2005-02-24 | 2006-08-30 | Neuro3D | Ocaperidone salt and pharmaceutical compositions containing the same |
-
2008
- 2008-09-03 MX MX2010001263A patent/MX2010001263A/en active IP Right Grant
- 2008-09-03 KR KR1020107004492A patent/KR101511398B1/en active IP Right Grant
- 2008-09-03 BR BRPI0816364A patent/BRPI0816364B8/en not_active IP Right Cessation
- 2008-09-03 ES ES08829253.7T patent/ES2439497T3/en active Active
- 2008-09-03 CN CN2008801053808A patent/CN101795694B/en active Active
- 2008-09-03 WO PCT/JP2008/065865 patent/WO2009031577A1/en active Application Filing
- 2008-09-03 JP JP2009531260A patent/JP4456177B2/en active Active
- 2008-09-03 US US12/676,291 patent/US8227430B2/en active Active
- 2008-09-03 EP EP08829253.7A patent/EP2184066B1/en active Active
-
2010
- 2010-09-30 HK HK10109375.4A patent/HK1142820A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614118A (en) * | 2012-03-15 | 2012-08-01 | 北京协和药厂 | Preparation method for epirubicin hydrochloride preparation for injection and preparation |
| CN102614118B (en) * | 2012-03-15 | 2014-04-30 | 北京协和药厂 | Preparation method for epirubicin hydrochloride preparation for injection and preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0816364B8 (en) | 2021-05-25 |
| EP2184066A1 (en) | 2010-05-12 |
| WO2009031577A1 (en) | 2009-03-12 |
| US8227430B2 (en) | 2012-07-24 |
| HK1142820A1 (en) | 2010-12-17 |
| US20100173862A1 (en) | 2010-07-08 |
| BRPI0816364A2 (en) | 2015-09-29 |
| EP2184066A4 (en) | 2012-08-01 |
| EP2184066B1 (en) | 2013-11-06 |
| KR20100051694A (en) | 2010-05-17 |
| BRPI0816364B1 (en) | 2020-10-13 |
| ES2439497T3 (en) | 2014-01-23 |
| JPWO2009031577A1 (en) | 2010-12-16 |
| MX2010001263A (en) | 2010-10-04 |
| KR101511398B1 (en) | 2015-04-24 |
| CN101795694B (en) | 2012-10-10 |
| JP4456177B2 (en) | 2010-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100396276C (en) | Compositions containing organic compounds | |
| US8871253B2 (en) | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt | |
| CN101785861A (en) | The Injectable composition that is used for the controllable release of pharmaceutically active compounds | |
| US11357728B2 (en) | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt | |
| CN101795694B (en) | Injection, injection solution and injection kit preparation | |
| KR920001773B1 (en) | A process for the preparation of an injectable solution containing anthracycline glycoside | |
| CN104507467B (en) | Liquid composition, its manufacturing method and the liquid preparation of the active constituent of methane series containing Japanese yew | |
| SK286421B6 (en) | Formulation of kahalalide F, kit, reconstituted and diluted solution comprising formulation and use | |
| Zhou et al. | The preparation of a complex of insulin–phospholipids and their interaction mechanism | |
| DE60025494T2 (en) | EPOTHILONE COMPOSITIONS | |
| CN102958519A (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| EP2934593B1 (en) | Cabazitaxel composition | |
| US11903934B2 (en) | Rifabutin treatment methods, uses, and compositions | |
| JP2001278788A (en) | Stable liquid preparation formulated with allantoin | |
| US11752165B2 (en) | Basic chemotherapeutic intratumour injection formulation | |
| JP2001163776A (en) | Stabilized liquid agent | |
| RU2236227C1 (en) | Stable pharmaceutical formulation of anticancer preparation | |
| CN104940189B (en) | The composition for treating hyperplasia disease | |
| CN1374857A (en) | Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins | |
| US6528524B2 (en) | Pharmaceutical compositions containing cinchonine dichlorhydrate | |
| RU2662087C1 (en) | Pharmaceutical antitumor composition based on salt olivomicine derivative | |
| JP2022548858A (en) | Methods of treatment, uses and compositions of rifabutin | |
| CN115487148A (en) | Ginsenoside mitoxantrone liposome, preparation method and application thereof | |
| CN114191387A (en) | Preparation method of voriconazole oral liquid | |
| CN104844530A (en) | Preparation of novel altretamine salt as well as pharmaceutical composition and clinical application of novel altretamine salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1142820 Country of ref document: HK |
|
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Tokyo, Japan, Japan Applicant after: Meiji Seika Pharma Co., Ltd. Address before: Tokyo, Japan, Japan Applicant before: Meiji Seika Kaisha, Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MEIJI SEIKA KAISHA, LTD. (JP) TOKYO, JAPAN TO: MEIJI SEIKA PHARMA CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1142820 Country of ref document: HK |